Good evening, you're listening to Markets Desk.
In the grain pits, wheat closed out the week under pressure across the board. Chicago soft red winter contracts shed nine to nearly thirteen cents on Friday, with the July contract finishing down more than twenty-seven cents on the week. Kansas City hard red winter futures followed suit, posting similar losses, leaving traders heading into the weekend with a decidedly bearish posture on the complex.
Turning to equities, Amalgamated Financial is drawing attention after an insider sale worth roughly one hundred thirty thousand dollars. Chief Financial Officer Jason Darby offloaded three thousand shares on June eleventh at a weighted average of forty-three dollars and thirty cents per share. That move comes after the stock had already climbed forty-nine percent, which naturally raises questions about where management sees fair value from here.
And in biotech, two names are generating chatter ahead of potential acquisition activity. Legend Biotech and BioNTech, both commercial-stage companies with established revenue streams, are being flagged by analysts as credible buyout candidates. In an environment where large-cap pharma is sitting on capital and facing pipeline pressure, commercial-stage targets with proven assets tend to attract serious attention.
That's the tape. Markets Desk, signing off the floor.
